KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Non-Current Receivables (2016 - 2018)

Historic Non-Current Receivables for Gsk (GSK) over the last 3 years, with Q4 2018 value amounting to $181.4 million.

  • Gsk's Non-Current Receivables fell 3979.89% to $181.4 million in Q4 2018 from the same period last year, while for Dec 2018 it was $181.4 million, marking a year-over-year decrease of 3979.89%. This contributed to the annual value of $188.3 million for FY2018, which is 3560.36% down from last year.
  • Per Gsk's latest filing, its Non-Current Receivables stood at $181.4 million for Q4 2018, which was down 3979.89% from $301.4 million recorded in Q4 2017.
  • Gsk's 5-year Non-Current Receivables high stood at $353.1 million for Q4 2016, and its period low was $181.4 million during Q4 2018.
  • Over the past 3 years, Gsk's median Non-Current Receivables value was $301.4 million (recorded in 2017), while the average stood at $278.6 million.
  • Per our database at Business Quant, Gsk's Non-Current Receivables tumbled by 1464.14% in 2017 and then plummeted by 3979.89% in 2018.
  • Quarter analysis of 3 years shows Gsk's Non-Current Receivables stood at $353.1 million in 2016, then dropped by 14.64% to $301.4 million in 2017, then tumbled by 39.8% to $181.4 million in 2018.
  • Its Non-Current Receivables stands at $181.4 million for Q4 2018, versus $301.4 million for Q4 2017 and $353.1 million for Q4 2016.